Clinical Trials Browser

Phase 3 × Esophageal Neoplasms × pembrolizumab × Clear all

NCT03189719 2024-10-15

KEYNOTE-590

Phase 3 Completed

749 enrolled 40 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT03933449 2023-03-29

KEYNOTE-181

Phase 3 Completed

123 enrolled 25 charts

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT02564263 2023-03-13

KEYNOTE-181

Phase 3 Completed

628 enrolled 27 charts 1 FDA

Gastrointestinal

Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms

NCT03881111 2020-02-11

KEYNOTE-590

Phase 3 Withdrawn

Gastrointestinal

Esophageal Neoplasms